Bionano Genomics Appoints Vince Wong to its Board of Directors
December 22 2021 - 8:05PM
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping
(OGM) solutions on the Saphyr® system and provider of the leading
software solutions for visualization, interpretation and reporting
of genomic data, today announced the appointment of Vincent Wong,
JD, MBA, to its board of directors.
Mr. Wong is currently the chief commercial officer at
Geneoscopy, Inc., a life sciences company focused on the
development of diagnostic tests for gastrointestinal health. He
joined Geneoscopy in March 2021 after almost 18 years at Roche
Diagnostics, where he held senior leadership roles across the
spectrum of commercial execution, including product marketing,
sales, strategy, business development, market access and
communications. His teams served physician groups, hospital
systems, patients, biopharma, retail pharmacies and payors in the
areas of diabetes, oncology, infectious disease and women's
health.
“We are thrilled to have Vince joining the board of directors,”
said Erik Holmlin, PhD, president and chief executive officer at
Bionano Genomics. “Vince brings a depth of experience in commercial
leadership, the pharmaceutical industry as well as market access
and clinical diagnostics commercialization that complements the
outstanding experience we already have across the board. I’m
excited to work closely with Vince as we ramp up our commercial
execution and advance efforts connected to market access for
OGM.”
“I am excited about joining Erik and his colleagues on the board
of directors at Bionano and going deeper into the genomics
industry.” Vince added, “a significant portion of my time at Roche
Diagnostics was in the Ventana business, which transformed anatomic
pathology by automating outdated and cumbersome workflows through
instrumentation and consumables, creating modernized workflows that
delivered enhanced testing efficiency and medical value for labs,
clinicians and patients. I believe Bionano can achieve something
similar through its efforts to consolidate workflows in
cytogenomics. I also believe the combination of OGM and
next-generation sequencing data can enable the development of
targeted therapeutics and is something the pharmaceutical industry
could potentially leverage.”
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that
can enable researchers and clinicians to reveal answers to
challenging questions in biology and medicine. The Company’s
mission is to transform the way the world sees the genome through
OGM solutions, diagnostic services and software. The Company offers
OGM solutions for applications across basic, translational and
clinical research. Through its Lineagen business, the Company also
provides diagnostic testing for patients with clinical
presentations consistent with autism spectrum disorder and other
neurodevelopmental disabilities. Through its BioDiscovery business,
the Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view. For more information, visit
www.bionanogenomics.com, www.lineagen.com or
www.biodiscovery.com.
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,”
“estimate,” “intend” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) convey uncertainty of future events or outcomes and
are intended to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things, our commercialization
strategy and execution, including Mr. Wong’s involvement, our
ability to achieve our objective of consolidating workflows in
cytogenomics, including by comparison to Ventana, and interest in
our technology by the pharmaceutical industry. Each of these
forward-looking statements involves risks and uncertainties. Actual
results or developments may differ materially from those projected
or implied in these forward-looking statements. Factors that may
cause such a difference include the risks and uncertainties
associated with: the impact of the COVID-19 pandemic on our
business and the global economy; general market conditions; changes
in the competitive landscape, including the introduction of
competitive technologies or improvements in existing technologies;
failure of OGM to accurately and consistently perform as observed
in published studies; changes in our strategic and commercial
plans; our ability to obtain sufficient financing to fund our
strategic plans and commercialization efforts; the ability of
medical and research institutions to obtain funding to support
adoption or continued use of our technologies; and the risks and
uncertainties associated with our business and financial condition
in general, including the risks and uncertainties described in our
filings with the Securities and Exchange Commission, including,
without limitation, our Annual Report on Form 10-K for the year
ended December 31, 2020 and in other filings subsequently made by
us with the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. We do not undertake any
obligation to publicly update any forward-looking statements,
whether as a result of the receipt of new information, the
occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1
(858) 366-3243amy@juniper-point.com
Media Relations:Michael SullivanSeismic+1 (503)
799-7520michael@teamseismic.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Apr 2023 to Apr 2024